ESR2 and breast carcinoma: Mukhopadhyay et al. showed that ER-β interaction with wild-type and mutant TP53 had a pro-proliferative and anti-proliferative effect, respectively, in breast cancer cell lines (including TNBC cells), suggesting the importance of the TP53 status as a determinant of the tumorigenic role of ER-β [101].